ホーム › 急性骨髄性白血病 › オハイオ › Cleveland
Cleveland、OHにおける急性骨髄性白血病の臨床試験
Clevelandとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Case Western Reserve University, Cleveland
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Case Western Reserve University, Cleveland
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Case Western Reserve University, Cleveland
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Case Western Reserve University, Cleveland
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Rainbow Babies and Childrens Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
被験者募集中第2相
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
被験者募集中第1/2相
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
被験者募集中第3相
- Rainbow Babies and Childrens Hospital, Cleveland
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
被験者募集中第1相
- Cleveland Clinic, Cleveland
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Rainbow Babies and Childrens Hospital, Cleveland
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- UH Seidman Cancer Center, Cleveland
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
被験者募集中第2/3相
- University Hospitals Cleveland Medical Center, Cleveland
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
被験者募集中第3相
- The Ohio State University Comprehensive Cancer Center (OSUCCC), Cleveland
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- University Hospitals Case Medical Center, Cleveland
- Cleveland Clinic, Cleveland
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
被験者募集中第1相
- Case Western Reserve University, Cleveland
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
被験者募集中第1/2相
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
- University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Institute, Cleveland
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
被験者募集中第1相
- Cleveland Clinic Cancer Center, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
被験者募集中観察研究
- University Hospitals Seidman Cancer Center, Cleveland
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Clevelandにおける他の研究
- 非小細胞肺癌43件の研究
- がん（全種類）36件の研究
- 乳がん35件の研究
- 前立腺がん34件の研究
- 心不全33件の研究
- 卵巣がん30件の研究
- 転移性癌30件の研究
- 肺がん26件の研究
- 大腸癌24件の研究
- 心血管疾患22件の研究
- 子宮内膜がん20件の研究
- クローン病19件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。